Document:

NLNK-2012.06.30-EX10.2

Exhibit 10.2

ISU Research Park
2503 South Loop Drive
Building 5
Ames, Iowa  50010
Phone 515.296.5555 
Fax 515.296.3520

Today’s Discoveries  .  . Tomorrow’s Medicines

June 27, 2012

Kenneth R. Lynn 
12908 Walmer Street
Overland Park, Kansas 66209

Dear Ken:
This will confirm our agreement concerning your resignation as Executive Vice President of Business Development of NewLink Genetics Corporation (“NewLink” or “Company”).  
		
	1.
	You hereby tender your voluntary resignation as Executive Vice President of Business Development, and the Company hereby accepts your resignation, effective June 27, 2012 (the “Effective Date”).  However you will continue to be an employee of the Company as described below.  

		
	2.
	As of the Effective Date, your Employment Agreement dated November 22, 2010, is terminated in its entirety and you will not be entitled to any benefits thereunder except as expressly provided herein. Without limiting the generality of the foregoing, you will not be entitled to any severance payment in connection with your resignation hereunder or any future termination of employment, and you will not be entitled to any bonus for 2012. 

		
	3.
	As of the Effective Date, you will become Head of Business Development pursuant to a separate letter agreement between you and NewLink. 

		
	4.
	Under your stock option agreements dated August 6, 2008, January 21, 2009, April 14, 2011 and January 19, 2012, your outstanding stock options will continue to vest during your Continuous Service (as defined in NewLink’s 2009 Equity Incentive Plan) (the “2009 Plan”).  Your rights with respect to your stock options will be governed by the 2009 Plan and your option agreements.  You may continue to participate in the Company’s 2010 Employee Stock Purchase Plan.  

Exhibit 10.2

		
	5.
	Your accrued vacation as of the Effective Date will carry over to your new position.  Any accrued vacation that you may have as of termination of your employment will be paid based on your salary in effect at that time and in accordance with the Company’s policy in effect at such time. 

		
	6.
	Your right to indemnification under your Indemnity Agreement dated November 22, 2010, will continue with respect to any claims that are based on any alleged acts or omissions in connection with your prior employment as Executive Vice President of Business Development and your employment as Head of Business Development, in each case subject to the terms and conditions of the Indemnity Agreement.

		
	7.
	Your Proprietary Information and Inventions Agreement dated April 5, 2010 shall remain in full force and effect.

		
	8.
	Your employment with the Company as Head of Business Development will be “at-will.”  This means that either you or the Company may terminate your employment at any time, with or without cause, with or without notice, and for any reason or no reason.  Any contrary representations or agreements, which may have been made to you, are superseded by this offer.  The “at will” nature of your employment described in this offer letter shall constitute the entire agreement between you and the Company concerning the nature and duration of your employment.  In addition, the fact that the rate of your salary or other compensation is stated in units of years or months and that your vacation and sick leave accrue annually or monthly does not alter the at-will nature of the employment, and does not mean and should not be interpreted to mean that you are guaranteed employment to the end of any period of time or for any period time.  The “at will” term of your employment with the Company can only be changed in a writing signed by you and the Chief Executive Officer of the Company.

Sincerely

/s/ Charles J. Link Jr.

Charles J. Link, Jr., M.D.
Chief Executive Officer

Accepted and agreed to:

/s/ Kenneth Lynn                
Kenneth R. LynnNLNK-2012.06.30-EX10.3

Exhibit 10.3

ISU Research Park
2503 South Loop Drive
Building 5
Ames, Iowa  50010
Phone 515.296.5555 
Fax 515.296.3520

Today’s Discoveries  .  . Tomorrow’s Medicines

July 26, 2012

Kenneth R. Lynn
12908 Walmer Street
Overland Park, KS 66209

Dear Ken,

On behalf of NewLink Genetics, I would like to and extend an offer to you for the position of Head of Business Development with NewLink Genetics. Your primary place of work would be your home office in Kansas; however, the expectation would be for you to be willing and able to travel up to 6 days per month, on average, including days present in Ames as well as attendance at business meetings and conferences, as may be reasonably required. Travel expense will continue to be reimbursed consistent with company policy, provided, however, that expense reimbursement in connection with travel between your home office in Kansas and Ames will be limited to $600 per month unless otherwise approved. You will be compensated at the rate $4,166.67 per pay period to be paid on a semi-monthly basis.  You would also be paid a $7,500 signing bonus.  This position would be a non-executive position and you will no longer be eligible for the executive bonus plan. 

Overview of the Compensation Package:

Base Salary:                 $100,000 for 30 hours per week effort
401(K):                    3% of contribution equal to $3,000
18 Days PTO + 8 Holiday
Total Package:                $103,000

You will also continue to be offered, NewLink’s attractive benefits package including group health insurance and a flexible spending tax savings plan. You will earn per pay 

period towards Paid Time Off which is equivalent to 18 days of Paid Time Off.  NewLink Genetics will continue to make a special company contribution to the 401(k) plan on your behalf equal to 3% of your total compensation each pay period. You will continue to be 100% vested in this special company contribution. You will receive the 401(k) contribution regardless of whether you defer any of your compensation into the plan. You may also continue to participate in our dental, life and/or disability plans.

We are looking forward to continuing to work with you and feel this will be a mutually rewarding relationship for yourself and NewLink Genetics.  This position would begin on June 28, 2012.  If this is agreeable, please sign one copy of this letter. 

If you have any questions, please don’t hesitate to call. I can be reached at (515)598-2932.

Sincerely,    

/s/ Ronee Wagener

Ronee Wagener, MBA, SPHR                ___/s/ Kenneth Lynn_____________
Human Resources Manager                Kenneth R. LynnExhibit 10.1

 

NOTE
AND WARRANT PURCHASE AGREEMENT

 

This NOTE AND WARRANT
PURCHASE AGREEMENT, dated as of August 13, 2012 (this “Agreement”), is entered into by and among BLUEFLY,
INC., a Delaware corporation (the “Company”), PRENTICE CONSUMER PARTNERS, LP, a Delaware limited partnership
(“Prentice”), and RHO VENTURES VI, L.P., a Delaware limited partnership (“Rho”). Each of
Prentice and Rho are from time to time referred to herein as an “Investor” and, collectively, the “Investors.”

 

RECITALS

 

WHEREAS, Prentice
desires to purchase from the Company, and the Company desires to issue and sell to Prentice, (i) secured subordinated promissory
notes in an aggregate principal amount of One Million Five Hundred Thousand Dollars ($1,500,000), in the form attached hereto as
Exhibit A (the “Prentice Notes”), together with (ii) a related warrant to acquire shares of the Company’s
common stock, par value $0.01 per share (the “Common Stock”), in the form attached hereto as Exhibit C
(the “Prentice Warrant”), in each case, on the terms, and subject to the conditions, contained herein.

 

WHEREAS, Rho
desires to purchase from the Company, and the Company desires to issue and sell to Rho, (i) secured convertible subordinated promissory
notes in an aggregate principal amount of One Million Five Hundred Thousand Dollars ($1,500,000), in the form attached hereto as
Exhibit B (the “Rho Notes,” and, together with the Prentice Notes, the “Notes”), together
with (ii) a related warrant to acquire shares of Common Stock, in the form attached hereto as Exhibit C (the “Rho
Warrant,” and, together with the Prentice Warrant, the “Warrants”), in each case, on the terms, and
subject to the conditions, contained herein.

 

As used in this Agreement,
the following terms shall have the following meanings: (i) the term “Initial Securities” shall mean, collectively,
the Notes and the Warrants, (ii) the term “Note Conversion Securities” shall mean the shares of Common Stock
or Subsequent Round Securities (as defined in the Rho Notes) issuable upon conversion of the Rho Notes, (iii) the term “Warrant
Conversion Securities” shall mean the shares of Common Stock issuable upon exercise of the Warrants, and (iv) the term
“Securities” shall mean, collectively, the Initial Securities, the Note Conversion Securities and the Warrant
Conversion Securities.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration for the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

ARTICLE
I

PURCHASE AND SALE OF INITIAL SECURITIES; STOCKHOLDER APPROVAL

 

SECTION
1.1 Initial Securities. Subject to the terms and conditions hereof, the Company hereby (a) issues and sells to Prentice,
and Prentice hereby purchases from the Company, the

 

    	 

    	 

    
 

Prentice
Notes and (b) issues and sells to Rho, and Rho hereby purchases from the Company, the Rho Notes. In consideration for the purchase
by the Investors of the Notes, the Company also hereby (x) issues and sells to Prentice, and Prentice hereby purchases from the
Company, the Prentice Warrants and (y) issues and sells to Rho, and Rho hereby purchases from the Company, the Rho Warrants. The
purchase and sale of the Initial Securities is sometimes referred to herein as the “Closing.”

 

SECTION
1.2 Purchase Price. The aggregate purchase price for the Initial Securities to be purchased by each Investor is the
amount set forth opposite such Investor’s name in Schedule 1 (the “Purchase Price”).

 

SECTION
1.3 Stockholder Approval.

 

(a)          The
Company shall take such actions as are reasonably necessary to obtain the Stockholder Approval (as defined below) with respect
to the conversion of the Rho Notes and the exercise of the Rho Warrant and the Prentice Warrant through an action by majority written
consent of the stockholders, to be signed and delivered by each of the Investors at or prior to Closing (the “Stockholder
Written Consent”). The Company shall prepare and file with the United States Securities and Exchange Commission (the
“Commission”) within 45 days after the Closing, an information statement relating to the Stockholder Written
Consent (the “Information Statement”). The Company shall use its reasonable best efforts to respond to any comments
of the Commission and to obtain effectiveness of the Information Statement as promptly as reasonably practicable. The Company shall
mail the Information Statement to each of the Company’s stockholders as promptly as reasonably practicable after responding
to all such comments received by the Commission to the satisfaction of the Commission.

 

(b)          The
Company will notify the Investors promptly of the receipt of any comments from the Commission for amendments or supplements to
the Information Statement, and will supply the Investors with copies of all correspondence between the Company or any of its representatives,
on the one hand, and the Commission, on the other hand, with respect to the Information Statement. If there shall occur any event
that should be set forth in an amendment or supplement to the Information Statement, the Company will promptly prepare and mail
to its stockholders such amendment or supplement. The Company will not mail any Information Statement, or any amendment or supplement
thereto, to which any Investor reasonably objects after being afforded the opportunity to review the same. The Investors shall
cooperate with the Company in the preparation of the Information Statement or in responding to any comments of the Commission,
and the Investors shall promptly notify the Company if any information supplied by it for inclusion in the Information Statement
shall have become false or misleading, and shall cooperate with the Company in disseminating the Information Statement, as so amended
or supplemented, to correct any such false or misleading information.

 

(c)          Each
Investor hereby agrees to vote or cause to be voted all shares of the Company’s voting stock that are beneficially owned
by such Investor, or over which such Investor has or shares voting control, and to cause every Affiliate (as such term is defined
in Rule 12b-2 of the Exchange Act) of the Investor to vote or cause to be voted, from time to time and at all times, in whatever
manner as shall be necessary to ensure that the Stockholder Approval is obtained,

 

    	2

    	 

    
 

including
without limitation, by delivering to the Company a Stockholder Written Consent that is duly executed by such Investor and each
of its Affiliates (as applicable) within 10 days of the Closing. “Stockholder Approval” means such approval
of the stockholders of the Company as may be necessary under the rules of the NASDAQ Capital Market or any other national securities
exchange or quotation system upon which the Common Stock may be listed from time to time, in order to permit (i) the exercise
in full of the conversion rights set forth in Section 5 of the Rho Notes (without giving effect to any limitation in such Section
5 relating to any such rules) and (ii) the exercise in full of the rights set forth in the Warrants.

 

SECTION
1.4 Use of Proceeds. The Company shall use the proceeds from the issuance of the Initial Securities solely for working
capital and general corporate purposes.

 

SECTION
1.5 Registration Rights. Rho shall be entitled to registration rights in respect of the Note Conversion Securities
and the Warrant Conversion Securities issuable upon exercise of the Rho Warrant, and, to the extent Rho exercises its rights under
this Section 1.5 by providing a Notice (as defined below), Prentice shall be entitled to simultaneous “piggy-back”
shelf registration rights in respect of the Warrant Conversion Securities issuable upon exercise of the Prentice Warrant, in each
case, consistent with the registration rights granted pursuant to the Amended and Restated Registration Rights Agreement, dated
as of September 7, 2011 (the “2011 Agreement”), by and among the Company and the other parties thereto, applied
mutatis mutandis, including, without limitation, the Company’s obligation to use its commercially reasonable efforts
to effect the registration contemplated by Section 2.2.1 of the 2011 Agreement; provided, however,
that (i) the Filing Deadline (as defined in the 2011 Agreement) with respect to the Company’s obligation to prepare and file
a shelf registration statement covering such securities shall be a date 60 days following the date of the Company’s receipt
of written notice (the “Notice”) from Rho requesting the registration of such securities (or 90 days following
the date of the Company’s receipt of the Notice if the Company determines that such longer period is reasonably necessary
to avoid filing a shelf registration statement including or incorporating by reference financial statements that do not comply
with the requirements of Rule 3-12 of Regulation S-X, as amended, or any successor rule) and (ii) the 180-day Required Effectiveness
Deadline (as defined in the 2011 Agreement) shall also commence on the first day following the Company’s receipt of the Notice;
and provided, further, however, that, notwithstanding anything to the contrary contained herein or
in the 2011 Agreement, the provisions of Section 2.2.4 and Section 2.2.5 of the 2011 Agreement shall be inapplicable to the registration
of the shares of Common Stock or Subsequent Round Securities issuable upon conversion of Notes contemplated by this Section 1.5.

 

ARTICLE
II

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company hereby
represents and warrants as of the date hereof (except for the representations and warranties that speak as of a specific date,
which shall be made as of such date), to the Investors that the following representations and warranties are true and complete,
except as set forth in the Schedules delivered herewith. The Schedules shall be arranged in sections corresponding to the numbered
sections contained in this Article II, and the disclosures in any section of the schedules shall qualify other sections in this
Article II to the extent it is reasonably apparent from a reading of the disclosure that such disclosure is applicable to such
other

 

    	3

    	 

    
 

sections.
Statements qualified by the “Company’s knowledge” or phrases of similar import means that such statement
is based upon the knowledge of the executive officers of the Company having responsibility for the matter or matters that are
the subject of the statements.

 

SECTION
2.1 Subsidiaries. The Company has no direct or indirect subsidiaries, other than (i) Eyefly, LLC, a Delaware limited
liability company in which it has a 52% membership interest and (ii) EVT Acquisition Co., LLC, a wholly-owned Delaware limited
liability company (collectively, the “Subsidiaries”).

 

SECTION
2.2 Organization and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or organized
(as applicable), validly existing and in good standing under the laws of the State of Delaware, with the requisite entity power
and authority to own or lease and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any of its Subsidiaries is in violation of any of the provisions of its certificate of incorporation or certificate
of formation or, in any material respects, its by-laws, operating agreement or other organizational or charter documents. Each
of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to have (i)
a material and adverse effect on the legality, validity or enforceability of this Agreement, the Notes or the Warrants (collectively,
the “Transaction Documents”), (ii) a material and adverse effect on the results of operations, assets, business,
condition (financial or otherwise) or liabilities (including contingent liabilities) of the Company or the Company and its Subsidiaries,
taken as a whole, or (iii) any adverse impairment to the Company’s ability to perform in any material respect on a timely
basis its obligations under the Transaction Documents (each of the items listed in clauses (i)-(iii), a “Material Adverse
Effect”).

 

SECTION
2.3 Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into
and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The Company’s execution and delivery of each of the Transaction Documents and the consummation
by it of the transactions contemplated hereby and thereby (including, but not limited to, (i) the sale and delivery of the Initial
Securities, (ii) the issuance of the Note Conversion Securities in accordance with the terms of the Rho Notes and (iii) the issuance
of the Warrant Conversion Securities in accordance with the terms of the Warrants) have been duly authorized by all necessary corporate
action on the part of the Company, and no further corporate action is required by the Company, its board of directors or its stockholders
in connection therewith other than in connection with (x) the Stockholder Approval and (y) any amendment to the Company’s
certificate of incorporation (as amended or restated from time to time) as may be necessary to increase the number of shares of
Common Stock authorized thereunder so as to enable the Company to issue Note Conversion Securities in connection with any Subsequent
Round of Financing (as defined in the Rho Notes) and the approval by the Company’s stockholders of any such amendment (a
“Charter Amendment”). Each of the Transaction Documents has been (or upon delivery will have been) duly executed
by the Company and is, or when delivered in accordance with the terms hereof, will constitute the legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i) as such enforceability

 

    	4

    	 

    
 

may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

SECTION
2.4 No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents and the consummation
by the Company of the transactions contemplated hereby or thereby (including, without limitation, (A) the sale and delivery of
the Initial Securities, (B) the issuance of the Note Conversion Securities in accordance with the terms of the Rho Notes and (C)
the issuance of the Warrant Conversion Securities in accordance with the terms of the Warrants) do not and will not (i) conflict
with or violate any provisions of the Company’s certificate of incorporation, by-laws or otherwise result in a violation
of the organizational documents of the Company, (ii) conflict with, result in any breach of any provision of, or constitute a default
(or an event that with notice or lapse of time or both would result in a default) under, result in the creation of any lien upon
any of the properties or assets of the Company or any of its Subsidiaries or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract, or (iii) subject to the
Stockholder Approval and any Charter Amendment, conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or any of its Subsidiaries
is subject (including federal and state securities laws and regulations and the rules and regulations, assuming the correctness
of the representations and warranties made by the Investors herein, of any self-regulatory organization to which the Company or
its securities are subject including all applicable trading markets), or by which any property or asset of the Company or any of
its Subsidiaries is bound or affected, except in the case of clauses (ii) and (iii) such as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. “Material Contract” means any contract of the Company
that was filed or required to be filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation
S-K, other than any contract which has expired by its terms and does not provide for the continuation of any material obligation
on the part of the Company following the date hereof.

 

SECTION
2.5 Filings, Consents and Approvals. The execution and delivery by the Company of the Transaction Documents, and
the performance by the Company of the transactions contemplated hereby and thereby, do not and will not require the Company to
effectuate or obtain any registration with, consent or approval of, or notice to any federal, state or other governmental authority
or regulatory body, other than periodic and other filings under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), all required filings with the NASDAQ Capital Market and, with respect to the transactions contemplated by Section
1.5, filings required under the Securities Act of 1933, as amended (the “Securities Act”). The parties hereto
agree and acknowledge that, in making the representations and warranties in the foregoing sentence of this Section 2.5,
the Company is relying on the representations and warranties made by the Investors in Article III.

 

SECTION
2.6 Issuance of Initial Securities. The Initial Securities have been validly issued, and, upon payment therefor,
will be fully paid and non-assessable. The Note Conversion

 

    	5

    	 

    
 

Securities,
when issued in accordance with the terms of the Rho Notes, will be validly issued, fully paid and non-assessable. The Warrant
Conversion Securities, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.
The offering, issuance, sale and delivery of (i) the Initial Securities as contemplated by this Agreement, (ii) the Note Conversion
Securities as contemplated by the Rho Note and (iii) the Warrant Conversion Securities as contemplated by the Warrants, is (or
will be), as applicable, exempt from the registration and prospectus delivery requirements of the Securities Act, are being (or
will be) , as applicable, made in compliance in all material respects with all applicable federal and state laws and regulations
concerning the offer, issuance and sale of securities, and are not being (or will not be), as applicable, issued in violation
of any preemptive or other rights of any stockholder of the Company. The parties hereto agree and acknowledge that, in making
the representations and warranties in the foregoing sentence of this Section 2.6, the Company is relying on the representations
and warranties made by the Investors in Article III.

 

SECTION
2.7 Capitalization. The aggregate number of shares and type of all authorized, issued and outstanding classes of
capital stock, options, warrants and other securities of the Company (whether or not presently convertible into or exercisable
or exchangeable for shares of capital stock of the Company) as of the Closing Date, is as set forth in the Capitalization Table
delivered to the Investors concurrently herewith (the “Capitalization Table”). All issued and outstanding shares
of capital stock are duly authorized, validly issued, fully paid and non-assessable and have been issued in compliance in all material
respects with all applicable federal and state securities laws and none of such outstanding securities were issued in violation
of any preemptive rights or similar rights to subscribe for or purchase any capital stock of the Company. The Capitalization Table
is true and accurate as of the Closing. Except as disclosed in the Capitalization Table, as of the Closing, the Company did not
have outstanding any other options, warrants, securities convertible into Common Stock, script rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable
for, or entered into any agreement giving any Person any right to subscribe for or acquire, any shares of Common Stock, or securities
or rights convertible or exchangeable into shares of Common Stock. Except as set forth in the Capitalization Table, and except
for customary adjustments as a result of stock dividends, stock splits, combinations of shares, reorganizations, recapitalizations,
reclassifications or other similar events, there are no preemptive rights, anti-dilution or price adjustment provisions contained
in any security issued and outstanding by the Company (or in any agreement providing rights to security holders) and the issuance
and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other
than the Investors) and will not result in a right of any holder of securities to adjust the exercise, conversion, exchange or
reset price under such securities. Except as set forth in the Capitalization Table, and except for the 2011 Agreement and the Company’s
amended and restated Voting Agreement, dated as of December 21, 2009, (A) there are no agreements or arrangements under which the
Company is obligated to register the sale of any of its securities under the Securities Act, (B) there are no agreements or arrangements
pursuant to which any person has any co-sale rights, subscription rights, rights of first refusal, rights of first offer, tag along
rights, or drag along rights, and (C) there are no agreements or arrangements relating to the voting of securities of the Company,
nor are there any other similar rights relating to the, registration, transfer, sale or voting of the securities of the Company.
To the Company’s knowledge, except as disclosed in the SEC Reports and any Schedules 13D or 13G filed with the

 

    	6

    	 

    
 

SEC
pursuant to Rule 13d-1 of the Exchange Act by reporting persons or in Schedule 2.7, as of the date hereof no person or
group of related persons beneficially owns (as determined pursuant to Rule 13d-3 under the Exchange Act), or has the right to
acquire, by agreement with or by obligation binding upon the Company, beneficial ownership of in excess of 5% of the outstanding
Common Stock.

 

SECTION
2.8 SEC Reports; Disclosure Materials. The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve
months preceding the date hereof on a timely basis or has received a valid extension of such time of filing and has filed any such
SEC Reports prior to the expiration of any such extension and has filed all reports, schedules, forms, statements and other documents
required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding
the date hereof. Such reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports
were required being collectively referred to herein as the “SEC Reports” and, together with this Agreement and
the Schedules to this Agreement, the “Disclosure Materials”. As of their respective dates (or, if amended or
superseded by a filing prior to the Closing Date, then on the date of such filing), the SEC Reports filed by the Company complied
in all material respects with the requirements of the Securities Act and the Exchange Act (as applicable) and the rules and regulations
of the Commission promulgated thereunder, and none of the SEC Reports, when filed (or, if amended or superseded by a filing prior
to the Closing Date, then on the date of such filing) by the Company, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. All material agreements to which the Company is a party or to which the
property or assets of the Company are subject are included as part of or identified in the SEC Reports, to the extent such agreements
are required to be included or identified pursuant to the rules and regulations of the Commission.

 

SECTION
2.9 Financial Statements. The financial statements of the Company included in the SEC Reports comply (or, to the
extent corrected by a subsequent restatement that is filed with the Commission prior to the date hereof, as corrected do comply)
in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with U.S. generally accepted accounting
principles, as applied by the Company (“GAAP”), applied on a consistent basis during the periods involved, except
as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, year-end audit adjustments.

 

SECTION
2.10 Tax Matters. The Company and each of its Subsidiaries has (i) prepared and filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) paid all taxes
and other governmental

 

    	7

    	 

    
 

assessments
and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those
being contested in good faith, with respect to which adequate reserves have been set aside on the books of the Company or its
Subsidiaries (as applicable) and (iii) set aside on its books provisions reasonably adequate for the payment of all taxes for
periods subsequent to the periods to which such returns, reports or declarations apply, except, in the case of clauses (i) and
(ii) above, where the failure to so pay or file any such tax, assessment, charge or return would not reasonably be expected to
have a Material Adverse Effect. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of
any jurisdiction and the officers of the Company know of no basis for any such claim.

 

SECTION
2.11 Material Changes; Undisclosed Events, Liabilities or Developments; Solvency. Since the date of the latest financial
statements included within the SEC Reports, except as specifically disclosed in the SEC Reports, (i) there have been no events,
occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate, a Material
Adverse Effect, (ii) there has not been any material change or amendment to, or any waiver of any material right by the Company
under, any Material Contract, (iii) all Material Contracts are in full force and effect except those that have expired by their
terms or as otherwise set forth in the SEC Reports and, to the Company’s knowledge, no party to any Material Contract is
in breach thereof in any material respect, (iv) the Company’s business has been operated in the ordinary course, (v) the
Company has not incurred any material liabilities other than (A) trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements
pursuant to GAAP or required to be disclosed in filings made with the Commission, (vi) the Company has not altered its method of
accounting or changed its auditors, except as disclosed in its SEC Reports, (vii) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders, in their capacities as such, or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock, and (viii) the Company has not issued any equity securities to
any officer, director or affiliate, except pursuant to existing Company stock-based plans. The Company has not taken any steps
to seek protection pursuant to any bankruptcy law and, to the Company’s Knowledge, none of its creditors intends to initiate
involuntary bankruptcy proceedings and there does not exist any fact which would reasonably lead a creditor to do so. Based on
the financial condition of the Company as of the Closing, after giving effect to transactions contemplated hereby to occur at the
Closing, the Company reasonably expects to have sufficient cash on hand to pay all of its currently foreseeable expenses for the
next twelve months.

 

SECTION
2.12 Environmental Matters. To the Company’s knowledge, neither the Company nor any of its Subsidiaries
(i) is in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court,
domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection
or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental
Laws”), (ii) owns or operates any real property contaminated with any substance that is in violation of any
Environmental Laws, (iii) is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or (iv) is
subject to any claim relating to any Environmental Laws; which, in the case of any of the matters described in clauses (i)
— (iv), has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
and, to the

 

    	8

    	 

    
 

Company’s
knowledge, there is no pending or threatened investigation that might lead to such a claim.

 

SECTION
2.13 Litigation. Except as set forth in Schedule 2.13, there is no action, suit, inquiry, notice of violation,
proceeding (including any partial proceeding such as a deposition) or investigation pending or threatened in writing against the
Company or any of its properties or any officer, director or employee of the Company acting in his or her capacity as an officer,
director or employee before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative
agency, regulatory authority, stock market, stock exchange or trading facility (“Action”) (and in the case of
any inquiry or investigation, to the Company’s knowledge) before or by any court, public board, government agency, self-regulatory
organization or body pending against or affecting the Company or any of its Subsidiaries, and no such Action is currently threatened
that could reasonably be expected to lead to the commencement of an Action. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities
Act.

 

SECTION
2.14 Contracts. Schedule 2.14 lists the following contracts, agreements, commitments or binding understanding,
whether oral or written (collectively, the “Contracts”), to which the Company or any of its Subsidiaries is
a party or subject or by which either the Company or any of its Subsidiaries is bound: (x) each employment related Contract, (y)
each Contract (A) with any Insider or (B) between or among any insiders relating in any way to the Company; and (iii) each Material
Contract. “Insider” means (i) each of Quantum Industrial Partners LDC, a Cayman Islands limited duration company,
SFM Domestic Investments LLC, a Delaware limited liability company, Maverick Fund USA, Ltd., a Texas limited partnership, Maverick
Fund, L.D.C., a Cayman Islands exempted limited duration company, Maverick Fund II, Ltd., a Cayman Islands exempted company, Prentice
Consumer Partners, LP, a Delaware limited partnership and Rho Ventures VI, L.P., (ii) any existing officer or director of the Company,
(iii) any member of the immediate family of the persons described in clause (i) or (iv) any entity in which any of the persons
described in clause (i), (ii) or (iii) owns any beneficial interest (other than less than one percent of the outstanding shares
of capital stock of any corporation whose stock is listed on a national securities trading market). The term “person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

SECTION
2.15 Employment Matters. No material labor dispute exists or, to the Company’s knowledge, is imminent with
respect to any of the employees of the Company or any of its Subsidiaries which would reasonably be expected to have a Material
Adverse Effect. The Company and each of its Subsidiaries is in compliance with all U.S. federal, state, local and foreign laws
and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.

 

SECTION
2.16 Employee Relations. Neither the Company, nor any of its Subsidiaries, is a party to any collective bargaining
agreement. To the Company’s knowledge, the Company’s and its Subsidiaries’ relations with their respective employees
are as disclosed in the SEC Reports.

 

    	9

    	 

    
 

Except
as disclosed in the SEC Reports or as the Investors have otherwise been made aware, no current executive officer of the Company
has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment
with the Company. To the Company’s knowledge, no executive officer of the Company is in violation of any material term of
any employment Contract, confidentiality, disclosure or proprietary information agreement, non- competition agreement, or any
other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not
subject the Company to any liability with respect to any of the foregoing matters.

 

SECTION
2.17 Labor Matters. The Company and each of its Subsidiaries is in compliance in all material respects with all federal,
state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions
of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect.

 

SECTION
2.18 Minute Books. The minute books of the Company for the period from 2001 to present, all of which have been made
available to the Investors, are complete and correct. The minute books of the Company contain, in all material respects, accurate
records of all meetings held and actions taken by the board of directors and committees of the board of directors of the Company
during such period, and no meeting of the board of directors or committees has been held for which minutes are not contained in
such minute books, other than meetings held within the last sixty (60) days for which minutes have not yet been prepared and/or
approved by the board of directors or applicable committee.

 

SECTION
2.19 Affiliate Transactions. Except as disclosed in the SEC Reports, no Insider has any agreement, contract, commitment
or binding understanding, whether oral or written, with the Company or any of its Subsidiaries (other than the employment agreements
filed with the Commission), any loan to or from the Company or any of its Subsidiaries or any interest in any assets (whether real,
personal or mixed, tangible or intangible) used in or pertaining to the business of the Company or any of its Subsidiaries (other
than ownership of capital stock of the Company). To the Company’s knowledge, except as set forth in the SEC Reports, no director
or officer has any direct or indirect interest in any supplier of the Company or any of its Subsidiaries or in any Person from
whom or to whom the Company or any of its Subsidiaries leases any property, or in any other Person with whom the Company or any
of its Subsidiaries otherwise transacts business of any nature, other than transactions entered into in the ordinary course of
business on the Company’s web site.

 

SECTION
2.20 Compliance. Neither the Company nor any of its Subsidiaries (i) is in default under or in violation of (and
no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company
or its Subsidiaries under), nor has the Company or any of its Subsidiaries received written notice of a claim that it is in default
under or that it is in violation of, any Material Contract (whether or not such default or violation has been waived), (ii) is
not in violation of any order of which the Company or its Subsidiaries has been made aware in writing of any court, arbitrator
or governmental body having jurisdiction over the Company, its Subsidiaries or their respective properties or assets, or (iii)
is in violation of, or in receipt of written notice that it is in violation of, any statute, rule or regulation of any governmental

 

    	10

    	 

    
 

authority
applicable to the Company or its Subsidiaries, except in each case as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

SECTION
2.21 Regulatory Permits. The Company and each of its Subsidiaries possesses or has applied for all certificates,
authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct
its business as currently conducted and as described in the SEC Reports, except where the failure to possess such permits, individually
or in the aggregate, has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect (“Material Permits”), and (i) neither the Company nor any of its Subsidiaries has received any notice
in writing of proceedings relating to the revocation or material adverse modification of any such Material Permits and (ii) to
the Company’s knowledge, there do not exist any facts or circumstances that would give rise to the revocation or material
adverse modification of any Material Permits.

 

SECTION
2.22 Title to Assets. Neither the Company nor any of its Subsidiaries owns any real property. Each of the Company
and its Subsidiaries has good and marketable title to all tangible personal property owned by it which is material to the business
of the Company, taken as a whole, free and clear of all liens (other than liens under the Company’s senior credit facility)
except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made
of such property by the Company or its Subsidiaries. Any real property and facilities held under lease by the Company or its Subsidiaries
are held by it under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with
the use made and proposed to be made of such property and buildings by the Company or its Subsidiaries (as applicable).

 

SECTION
2.23 Insurance. The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as are prudent and customary in the businesses and locations in which the Company
or its Subsidiaries is engaged.

 

SECTION
2.24 Patents and Trademarks. The Company and each of its Subsidiaries owns, possesses, licenses or has other rights
to use all foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations, trade
names, copyrights, inventions, trade secrets, technology, Internet domain names, know-how and other intellectual property (collectively,
the “Intellectual Property”) necessary for the conduct of its business as now conducted, as described in the
SEC Reports (the “Company Intellectual Property”). Except as set forth in the SEC Reports, (a) to the Company’s
knowledge, there are no rights of third parties to any such Company Intellectual Property that is owned by the Company or its Subsidiaries;
(b) to the Company’s knowledge, there is no pending or threatened Action by others challenging the Company’s or its
Subsidiaries’ rights in or to any such Company Intellectual Property that could reasonably be expected to have a Material
Adverse Effect; and (c) to the Company’s knowledge, there is no pending or threatened Action by others that the Company or
its Subsidiaries infringes or otherwise violates any Intellectual Property of others that could reasonably be expected to have
a Material Adverse Effect.

 

    	11

    	 

    
 

SECTION
2.25 Internal Accounting Controls; Disclosure Controls. Except as has not had or would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect, the Company (i) has established and maintained disclosure
controls and procedures and internal control over financial reporting (as such terms are defined in paragraphs (e) and (f), respectively,
of Rule 13a-15 under the Exchange Act) as required by Rule 13a-15 under the Exchange Act, and (ii) has disclosed, based on its
most recent evaluations, to its outside auditors and the audit committee of the board of directors of the Company (A) all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting (as defined in Rule
13a-15(f) of the Exchange Act) that are reasonably likely to adversely affect the Company’s ability to record, process, summarize
and report financial data, and (B) any fraud known to the Company, whether or not material, that involves management or other employees
who have a significant role in the Company’s internal controls over financial reporting.

 

SECTION
2.26 Sarbanes-Oxley. The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley
Act of 2002 which are applicable to it, except where such noncompliance would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.

 

SECTION
2.27 Foreign Corrupt Practices. Neither the Company, nor its Subsidiaries, nor, to the Company’s knowledge,
any director, officer, agent, employee or other Person acting on behalf of the Company or its Subsidiaries has, in the course of
its actions for, or on behalf of, the Company or its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee or to any foreign or domestic political parties or campaigns from corporate
funds; (iii) violated or is in violation in any material respect of any provision of the U.S. Foreign Corrupt Practices Act of
1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any
foreign or domestic government official or employee.

 

SECTION
2.28 Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company
or any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company
in its SEC Filings and is not so disclosed or that otherwise would reasonably be expected to have a Material Adverse Effect.

 

SECTION
2.29 Indebtedness. Except as disclosed in the SEC Reports or as incurred pursuant to transactions entered into in
the ordinary course of business including draws under the senior credit facility, since June 30, 2012, neither the Company nor
any of its Subsidiaries (i) has any outstanding indebtedness, and (ii) is in violation of any term of or is in default under any
contract, agreement or instrument relating to any indebtedness, except where such violations and defaults would not reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Effect.

 

SECTION
2.30 Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Article III of this Agreement, no registration under the Securities Act is required for the offer and sale of the Initial Securities
by the Company to the Purchasers under the Transaction Documents.

 

    	12

    	 

    
 

SECTION
2.31 Registration Rights. Other than as set forth in the SEC Reports and the Transaction Documents, no Person has
any right to cause the Company to effect the registration under the Securities Act of any securities of the Company other than
those securities which are currently registered on an effective registration statement on file with the Commission.

 

SECTION
2.32 Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the Exchange
Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor
has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not,
in the twelve months preceding the date hereof, received written notice from any trading market on which the Common Stock is listed
or quoted to the effect that the Company is not in compliance in all material respects with the listing and maintenance requirements
for continued trading of the Common Stock on the NASDAQ Capital Market.

 

SECTION
2.33 Disclosure. The Company acknowledges and agrees that the Investors have not made any representations or warranties
with respect to the transactions contemplated hereby other than those set forth in the Transaction Documents.

 

SECTION
2.34 Brokers. Except for the payment of the Origination Fee, neither the Company, nor any of its officers, directors
or employees, has employed any broker or finder, or incurred any liability for any brokerage fees, commissions, finder’s
or other similar fees or expenses in connection with the transactions contemplated hereby.

 

ARTICLE
III

REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

 

Each Investor hereby
represents and warrants, severally as to itself and not jointly, to the Company as follows:

 

SECTION
3.1 Organization; Authority. Such Investor is a an entity duly formed, validly existing and in good standing under
the laws of the jurisdiction set forth next to its name on Schedule 1, with the requisite power and authority to enter into
and to consummate the transactions contemplated by this Agreement and the other Transaction Documents to which it is a party and
otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance by such Investor of the
transactions contemplated by this Agreement and the other Transaction Documents to which it is a party have been duly authorized
by all necessary action on the part of such Investor, and no further action is required by such Investor (or its respective managing
member or general partner, if applicable) in connection therewith. This Agreement and the other Transaction Documents to which
such Investor is a party have been duly executed by such Investor, and when delivered by such Investor in accordance with the terms
hereof and thereof, each will constitute the valid and legally binding obligation of such Investor, enforceable against it in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by
other equitable principles of general application.

 

    	13

    	 

    
 

SECTION
3.2 No Conflicts. The execution, delivery and performance by such Investor of this Agreement and the other Transaction
Documents to which it is a party and the consummation by such Investor of the transactions contemplated hereby and thereby will
not (i) result in a violation of the formation documents of such Investor, (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform
its obligations hereunder.

 

SECTION
3.3 Filings, Consents and Approvals. Such Investor is not required to obtain any consent, waiver, authorization or
order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other person in connection with the execution, delivery and performance by such Investor of the Transaction Documents.

 

SECTION
3.4 Investment Representations. Such Investor acknowledges that the offer and sale of the Securities to such Investor
have not been registered under the Securities Act, or the securities laws of any state or regulatory body, are being offered and
sold in reliance upon exemptions from the registration requirements of the Securities Act and such laws and may not be transferred
or resold without registration under such laws unless an exemption is available.

 

(a)          Such
Investor is acquiring the Securities for investment, and not with a view to the resale or distribution thereof, and is acquiring
the Securities for its own account.

 

(b)          Such
Investor is an “accredited investor” (as that term is defined in Rule 501 of Regulation D promulgated under the Securities
Act). Such Investor acknowledges that it has had the opportunity to review the Disclosure Materials and has been afforded (i) the
opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning
the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access
to information about the Company and its financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company
possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with
respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Investor or its
representatives or counsel shall modify, amend or affect such Investor’s right to rely on the truth, accuracy and completeness
of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction Documents. Such
Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect
to its acquisition of the Securities. Such Investor acknowledges and agrees that the Company has not made any representations or
warranties with respect to the transactions contemplated hereby other than those set forth in the Transaction Documents.

 

    	14

    	 

    
 

(c)          Such
Investor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment. Such Investor is able to bear the economic risk of an investment in the Securities
and, at the present time, is able to afford a complete loss of such investment.

 

(d)          Neither
such Investor, nor any of its principal owners, partners, members, directors or officers is included on the Office of Foreign Assets
Control list of foreign nations, organizations and individuals subject to economic and trade sanctions, based on U.S. foreign policy
and national security goals, or a person named on the list of known or suspected terrorists, terrorist organizations or other sanctioned
persons issued by the U.S. Treasury Department’s Office of Foreign Assets and Control.

 

SECTION
3.5 Reliance on Exemptions. Such Investor understands that the Securities being offered and sold to it in reliance
on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and such Investor’s compliance with, the representations, warranties,
agreements, acknowledgements and understandings of such Investor set forth herein in order to determine the availability of such
exemptions and the eligibility of such Investor to acquire the Securities.

 

SECTION
3.6 No Governmental Review. Such Investor understands that no United States federal or state agency or any other
government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or
suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of
the Securities.

 

SECTION
3.7 Office. Such Investor’s office in which its investment decision with respect to the Securities was made
is located at the address set forth opposite its name on Schedule 1.

 

SECTION
3.8 Brokers. Neither the Investors, nor any of their officers, directors or employees, has employed any broker or
finder, or incurred any liability for any brokerage fees, commissions, finder’s or other similar fees or expenses in connection
with the transactions contemplated hereby.

 

SECTION
3.9 Disclosure. The Investors acknowledge and agree that the Company has not made any representations or warranties
with respect to the transactions contemplated hereby other than those set forth in the Transaction Documents.

 

ARTICLE
IV

SURVIVAL; INDEMNIFICATION

 

SECTION
4.1 Survival. The representations and warranties contained in Articles II and III hereof shall survive the
Closing and the delivery of the Notes.

 

SECTION
4.2 Indemnification.

 

    	15

    	 

    
 

(a)          Indemnification
of the Investors. The Company will indemnify and hold each Investor and its respective directors, officers, stockholders, members,
partners, employees and agents (and any other persons with a functionally equivalent role of a person holding such titles notwithstanding
a lack of such title or any other title), each person who controls such Investor (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and
any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any
other title) of such controlling person (each, an “Investor Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs
and reasonable attorneys’ fees and costs of investigation that such Investor Party may suffer or incur arising from or relating
to any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents. The Company will not be liable to any Investor Party under this Agreement to the extent, but only to the extent that
a loss, claim, damage or liability is attributable to such Investor Party’s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents.

 

(b)          Indemnification
of the Company. Each Investor will severally and not jointly indemnify and hold the Company and its directors, officers, stockholders,
members, partners, employees and agents (and any other persons with a functionally equivalent role of a person holding such titles
notwithstanding a lack of such title or any other title), each person who controls the Company (within the meaning of Section 15
of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners
or employees (and any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack
of such title or any other title) of such controlling person (each, a “Company Party”) harmless from any and
all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid
in settlements, court costs and reasonable attorneys’ fees and costs of investigation that the Company Party may suffer or
incur arising from or relating to any of the representations, warranties, covenants or agreements made by such Investor in this
Agreement or in the other Transaction Documents.

 

SECTION
4.3 Conduct of Indemnification Proceedings. Promptly after receipt by any party (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 4.2(a) or (b), such Indemnified Person shall promptly
notify the Company and the other Investor or if the Indemnified Person is the Company, shall notify the Investors, as applicable
(the party against whom indemnity may be sought hereinafter referred to as the “Indemnifying Person”), in writing
and the Indemnifying Person shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such
Indemnified Person, and shall assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified
Person to so notify the Indemnifying Person shall not relieve the Indemnifying Person of its obligations hereunder except to the
extent that the Indemnifying Person is actually and materially and adversely prejudiced by such failure to notify. In any such
proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall
be at the expense of such Indemnified Person unless: (i)

 

    	16

    	 

    
 

the
Indemnifying Person and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Indemnifying
Person shall have failed promptly to assume the defense of such proceeding and to employ counsel reasonably satisfactory to the
Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel to the Indemnified Person, there exists
or shall exist a conflict of interest that would make it inappropriate for the same counsel to represent both the Indemnified
Person and the Indemnifying Person. The Indemnifying Person shall not be liable for any settlement of any proceeding effected
without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned unless the Indemnifying
Person fails to defend any proceeding or fails to promptly respond to a settlement offer. Without the prior written consent of
the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Indemnifying Person shall
not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have
been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional
release of such Indemnified Person from all liability arising out of such proceeding.

 

ARTICLE
V

CONDITIONS PRECEDENT TO CLOSING

 

SECTION
5.1 Conditions Precedent to the Obligations of the Investors at Closing. The obligation of each Investor to purchase
the Initial Securities opposite its respective name on Schedule 1 at the Closing is subject to the fulfillment, on or prior to
the date hereof (the “Closing Date”), of each of the following conditions, any of which may be waived by an
Investor as with respect to its obligations:

 

(a)          Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects as of the Closing Date, except for such representations and warranties that speak as of a specific date, in which case
such representations and warranties shall have been true and correct in all material respects as of such date.

 

(b)          Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to Closing.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated in the Transaction Documents.

 

(d)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Initial Securities at the Closing, all of which shall be and remain so long as
necessary in full force and effect.

 

(e)          No
Suspensions of Trading in Common Stock; Listing. The Common Stock (i) shall be designated for quotation or listed on the NASDAQ
Capital Market and (ii) shall not have been suspended, as of the Closing Date, by the Commission or the NASDAQ Capital Market

 

    	17

    	 

    
 

from
trading on the NASDAQ Capital Market nor shall suspension by the Commission or the NASDAQ Capital Market have been threatened,
as of the Closing Date, either (A) in writing by the Commission or the NASDAQ Capital Market or (B) by falling below the minimum
listing maintenance requirements of the NASDAQ Capital Market.

 

(f)          Company
Deliverables. The Company shall have issued, delivered or caused to have been delivered to the Investors each of the following:

 

(i)          each
of the Transaction Documents, duly executed by the Company;

 

(ii)          a
legal opinion of counsel to the Company, dated as of the Closing Date, executed by such counsel and addressed to the Investors;

 

(iii)          a
certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing Date,
(a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving
the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities, (b) certifying
the current versions of the certificate of incorporation, as amended, and by-laws, as amended of the Company and (c) certifying
as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company;

 

(iv)          a
certificate evidencing the formation and good standing of the Company in the State of Delaware issued by the Secretary of State
(or comparable office) of such jurisdiction, as of a date within five (5) business days of the Closing Date;

 

(v)          a
certificate evidencing the Company’s qualification as a foreign corporation in good standing issued by the States of New
York and Ohio, as of a date within five (5) business days of the Closing Date; and

 

(g)          Compliance
Certificate. The Company shall have delivered to the Investors a certificate, dated as of the Closing Date and signed by its
Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections
5.1(a) and 5.1(b).

 

SECTION
5.2 Conditions Precedent to the Obligations of the Company at Closing. The Company’s obligation to sell and
issue the Initial Securities at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the
Closing Date of the following conditions, any of which may be waived by the Company:

 

(a)          Representations
and Warranties. The representations and warranties of the Investors contained herein shall be true and correct in all material
respects as of the Closing Date, except for such representations and warranties that speak as of a specific date, in which case
such representations and warranties shall have been true and correct in all material respects as of such date.

 

    	18

    	 

    
 

(b)          Performance.
The Investors shall have performed, satisfied or complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by the Investors at or prior to Closing.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated in the Transaction Documents.

 

(d)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Initial Securities at the Closing, all of which shall be and remain so long as
necessary in full force and effect.

 

(e)          Investor
Deliverables. Each Investor shall have delivered or caused to have been delivered to the Company the following:

 

(i)          each
of the Transaction Documents to which such Investor is a party, duly executed by such Investor; and

 

(ii)          the
Purchase Price in United States dollars and in immediately available funds, by wire transfer to an account designated in writing
to the Investors by the Company for such purpose.

 

ARTICLE
VI

MISCELLANEOUS

 

SECTION
6.1 Fees and Expenses.

 

(a)          At
the Closing, the Company shall reimburse the Investors for their reasonable legal fees and expenses incurred in connection with
the transactions contemplated by this Agreement; provided, however, that (i) in no event shall the Investors be entitled
to receive in the aggregate an amount from the Company pursuant to this Section 5.1(a) in excess of $40,000 and (ii) each
Investor shall provide the Company with reasonably detailed invoices for such fees and expenses. Other than as provided with respect
to legal fees and expenses described in the immediately preceding sentence, each Investor shall pay the fees and expenses of their
respective advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection
with the negotiation, preparation, execution, delivery and performance of this Agreement and the other Transaction Documents.

 

(b)          At
the Closing, the Company shall pay to Prentice by wire transfer of immediately available funds an origination fee of Thirty Thousand
Dollars ($30,000) (the “Origination Fee”).

 

SECTION
6.2 Publicity. Except as may be required by applicable law or the rules of any securities exchange or market on which
securities of the Company are traded, no party hereto shall issue a press release or public announcement or otherwise make any
disclosure concerning this

 

    	19

    	 

    
 

Agreement
and the transactions contemplated hereby, without prior approval of the others; provided, however, that nothing in this
Agreement shall restrict the Company or any Investor from disclosing such information (a) that is already publicly available,
(b) to the extent required or appropriate in response to any summons or subpoena or to comply with applicable law, regulations
or the rules of any national securities exchange or quotation system (provided that the disclosing party will use commercially
reasonable efforts to notify the other parties in advance of such disclosure under this clause (b) so as to permit the
non-disclosing parties, in the case of a summons or subpoena, seek a protective order or otherwise contest such disclosure, and
the disclosing party will use commercially reasonable efforts to cooperate, at the expense of the non-disclosing parties, in pursuing
any such protective order) or (c) in connection with any litigation involving disputes as to the parties’ respective rights
and obligations hereunder.

 

SECTION
6.3 Entire Agreement. This Agreement and the other Transaction Documents constitute the entire Agreement between
the parties hereto with respect to the subject matter hereof and supersede all previous negotiations, commitments and writings
with respect to such subject matter.

 

SECTION
6.4 Assignments; Parties in Interest. Neither this Agreement nor any of the rights, interests or obligations hereunder
may be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the
other parties. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing herein, express
or implied, is intended to or shall confer upon any person not a party hereto any right, benefit or remedy of any nature whatsoever
under or by reason hereof, except as otherwise provided herein.

 

SECTION
6.5 Amendments. This Agreement may not be amended or modified except by an instrument in writing signed by, or on
behalf of, the parties against whom such amendment or modification is sought to be enforced.

 

SECTION
6.6 Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience of reference only
and do not constitute a part of and shall not be utilized in interpreting this Agreement.

 

SECTION
6.7 Notices and Addresses. Any and all notices or other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission,
if such notice or communication is delivered via facsimile (provided the sender receives a machine-generated confirmation of successful
transmission) at the facsimile number specified in this Section 6.7 prior to 5:00 p.m., Eastern Standard Time, on a business day,
(b) the next business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
number specified in this Section 6.7 on a day that is not a Trading Day or later than 5:00 p.m., Eastern Standard Time, on any
business day, (c) the business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
with next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as follows:

 

    	20

    	 

    
 

		To Company:	Bluefly, Inc.

			42 West 39th Street, 9th Floor

			New York, New York 10018

		Fax:	(212) 840-1903

		Attn:	General Counsel

 

			With a copy to:

 

			Dechert LLP

30 Rockefeller Plaza

New York, NY 10112-2200

		Fax:	(212) 698-3599

		Attn:	Richard A. Goldberg, Esq.

 

		To the Investors:	To the address set forth on Schedule
1;

 

With a copy to:

 

			Goodwin Procter LLP

			The New York Times Building

620 Eighth Avenue

New York, NY 10112-2200

		Fax:	(212) 355-3333

		Attn:	Stephen M. Davis, Esq.

 

SECTION
6.8 Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent
jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the
application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the
parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable
provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

 

SECTION
6.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to
the principles of conflicts of law thereof. Each party agrees that all proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, employees or agents) shall be commenced exclusively in the applicable courts located in the
State of New York. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the applicable courts located
in the County of New York, State of New York for the adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any proceeding, any claim that it is not personally subject to the jurisdiction
of any such courts located in the County of New York, State

 

    	21

    	 

    
 

of
New York, or that such proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably
waives personal service of process and consents to process being served in any such proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

SECTION
6.10 Execution; Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party
and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission, or by e-mail delivery of a “.pdf’ format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile signature page were an original thereof.

 

[Signature Page
Follows]

 

    	22

    	 

    
 

IN WITNESS
WHEREOF, this Agreement has been duly executed on the date first set forth above.

 

	 	BLUEFLY, INC.
	 	 
	 	By:	/ s / Joseph Park
	 	 	Name:	Joseph Park
	 	 	Title:	CEO
	 	 	 	 
	 	RHO VENTURES VI, L.P.
	 	 
	 	By: RMV VI, L.L.C., its General Partner
	 	 
	 	By: Rho Capital Partners LLC, its Managing Member
	 	 	 	 
	 	By:	/ s / Jeffrey Martin
	 	 	Name:	Jeffrey Martin
	 	 	Title:	Attorney-in-fact
	 	 	 	 
	 	PRENTICE CONSUMER PARTNERS, LP
	 	 
	 	By: Prentice Consumer Partners GP, LLC, its General Partner
	 	 	 	 
	 	By:	/ s / Mario Ciampi
	 	 	Name:	Mario Ciampi
	 	 	Title:	Managing Partner

 

    	23

    	 

    
  

SCHEDULE
1

 

investors

 

	Name
    and Address of Investor	Aggregate
    Principal 
 Amount of Note	Shares
    of Common Stock Issuable upon Exercise of Warrants	Aggregate
    Purchase Price
	
        Prentice
        Consumer Partners, LP

        623 Fifth Avenue, 32nd Floor

        New York, NY 10022

         
	$1,500,000	476,190	$1,500,000
	
        Rho
        Ventures VI, L.P.

        152
        West 57th Street, 23rd Floor

        New
        York, NY 10022

         
	$1,500,000	476,190	$1,500,000
	TOTAL	$3,000,000	952,380	$3,000,000

 

    	 

    	 

    
 

Disclosure Schedules

 

These Disclosure Schedules
are being furnished to the Investors in connection with the execution and delivery of the Note and Warrant Purchase Agreement,
dated August 13, 2012, by and among Bluefly, Inc., a Delaware corporation (the “Company”) and the Investors
(the “Agreement”). All capitalized terms used in these Disclosure Schedules have the meanings used in the Agreement,
unless otherwise indicated.

 

No reference to or
disclosure of any item or other matter in these Disclosure Schedules shall be construed as an admission to any third party or indication
to any third party that such item or other matter is material or would have a material adverse effect or that such item or other
matter is required to be referred to or disclosed in these Disclosure Schedules. No disclosure in these Disclosure Schedules relating
to any possible breach, violation or conflict of any contract or legal requirement shall be construed as an admission or indication
that any such breach, violation or conflict exists or has actually occurred. Matters reflected in these Disclosure Schedules are
not necessarily limited to matters required by the Agreement to be reflected in these Disclosure Schedules.

 

    	 

    	 

    
 

SCHEDULE
2.7

 

CAPITALIZATION

 

None.

 

    	 

    	 

    
 

SCHEDULE
2.13

 

LITIGATION

 

The Company is currently party to the following
Actions:

 

		1.	Bluefly, Inc. v. Love from Australia, LLC and Stuart Rush, Supreme Court of the State of New York, County of New York.
	 	 	 

		2.	Center for Environmental Health v. Two’s Company, Inc., et al, Superior Court of the State of California, County of Alameda.
	 	 	 

		3.	Select Retrieval, LLC v. Amerimakr Direct LLC et al, U.S. District Court for the District of Delaware.
	 	 	 

In addition, the Company from time to time
receives communications regarding threatened Actions alleging that the Company’s e-commerce and related activities infringement
upon various patents that purport to cover methods and practices that are commonly used by most participants in the ecommerce industry.
While one or more of these communications could reasonably be expected to lead to an Action regarding such infringement allegations,
the Company does not believe that any such Action could reasonably be expected to have a Material Adverse Effect.

 

    	 

    	 

    
 

SCHEDULE
2.14

 

CONTRACTS

 

Investment Agreement, dated November 13,
2000, by and among the Company, Bluefly Merger Sub, Inc., Quantum Industrial Partners LDC and SFM Domestic Investments LLC.

 

Common Stock and Warrant Purchase Agreement,
dated May 24, 2002, by and between the Company and the investors listed on Schedule 1 thereto.

 

Note and Warrant Purchase Agreement, dated
January 28, 2003, by and between the Company and the investors listed on Schedule 1 thereto.

 

Common Stock and Warrant Purchase Agreement
dated January 9, 2004 by and among the Company and the Investors listed on Schedule 1 thereto.

 

Master Service Agreement, dated as of February
28, 2005, by and between the Company and Level 3 Communications, LLC.

 

Customer Order Addendum, dated as of February
28, 2005, by and between the Company and Level 3 Communications, LLC.

 

Preferred Stock and Warrant Purchase Agreement,
dated as of June 24, 2005, by and among the Company and the Investors listed on the signature page thereto.

 

Amended and Restated Credit Agreement,
dated as of June 17, 2011, by and between the Company and Wells Fargo Bank, National Association

 

Amended and Restated Security Agreement,
dated as of June 17, 2011, by and between the Company and Wells Fargo Bank, National Association

 

Stock Purchase Agreement, dated as of June
5, 2006, by and among Bluefly, Inc., Quantum Industrial Partners LDC, SFM Domestic Investments, LLC and the investors listed on
the signature pages attached thereto.

 

Fee Letter, dated June 5, 2006, by and
among Bluefly, Inc., Quantum Industrial Partners LDC and SFM Domestic Investments, LLC.

 

Master License Agreement, dated as of September
28, 2006, by and between the Company and Art Technology Group, Inc.

 

Fulfillment Services Agreement, dated as
of April 11, 2007, by and between the Company and Fulfillment Technologies, LLC.

 

Service Agreement, dated as of May 9, 2007,
by and between the Company and VIPdesk Connect, Inc.

 

    	 

    	 

    
 

Letter Agreement, dated as of December
21, 2007, by and between the Company and Fulfillment Technologies, LLC.

 

Third Amended and Restated Employment Agreement,
dated as of May 3, 2011, by and between the Company and Kara B. Jenny.

 

Standby Commitment Agreement, dated as
of March 26, 2008, by Quantum Industrial Partners LDC, SFM Domestic Investments LLC and private funds associated with Maverick
Capital, Ltd. in favor of the Company.

 

Amended and Restated Warrant No. 1, dated
April 8, 2008 and effective as of March 26, 2008, issued to Quantum Industrial Partners LDC.

 

Amended and Restated Warrant No. 2 dated
April 8, 2008 and effective as of March 26, 2008, issued to SFM Domestic Investments LLC.

 

Amended and Restated Warrant No. 3 dated
April 8, 2008 and effective as of March 26, 2008, issued to Maverick Fund USA, Ltd.

 

Amended and Restated Warrant No. 4 dated
April 8, 2008 and effective as of March 26, 2008, issued to Maverick Fund LDC.

 

Amended and Restated Warrant No. 5 dated
April 8, 2008 and effective as of March 26, 2008, issued to Maverick Fund II, Ltd.

 

Letter Agreement, dated as of November
19, 2008, by and between the Company and Fulfillment Technologies, LLC

 

Securities Purchase Agreement, dated as
of December 21, 2009, between Bluefly, Inc. and Rho Ventures VI, LP

 

Amended and Restated Voting Agreement,
dated as of December 21, 2009, among Bluefly, Inc., Quantum Industrial Partners LDC, SFM Domestic Investments, LLC, Maverick Fund
USA, Ltd., Maverick Fund, L.D.C., Maverick Fund II, Ltd., Prentice Capital Partners, LP, Prentice Capital Partners QP, LP, Prentice
Capital Offshore, Ltd., S.A.C. Capital Associates, LLC, GPC XLIII, LLC, PEC I, LLC and Rho Ventures VI, LP

 

Lease Agreement by and between the Company
and 42-52 West 39 Street LLC, dated March 17, 2010

 

Operating Agreement of Eyefly LLC, dated
as of January 4, 2011

 

Management Services Agreement, dated as
of January 4, 2011, by and between Eyefly LLC and the Company

 

    	 

    	 

    
 

Management Services Agreement, dated as
of January 4, 2011, by and between Eyefly LLC and Tworoger Associates, Ltd.

 

Second Amended and Restated Employment
Agreement, dated as of May 3, 2011, by and between the Company and Cristyn Girolami

 

Third Amended and Restated Employment Agreement,
dated as of May 3, 2011, by and between the Company and Martha Ottavio

 

Second Amended and Restated Employment
Agreement, dated as of May 3, 2011, by and between the Company and Martin Keane

 

Amended and Restated Employment Agreement,
dated as of February 2, 2012, by and between the Company and Joseph Park

 

Separation Agreement, dated February 2,
2012, by and between Bluefly, Inc. and Melissa Payner-Gregor

 

Securities Purchase Agreement dated as
of September 7, 2011, by and among the Company and each of the Purchasers named on Schedule 1 thereto

 

Amended and Restated Registration Rights
Agreement dated as of September 7, 2011, by and among the Company, Quantum Industrial Partners LDC, SFM Domestic Investments, LLC,
Maverick Fund USA, Ltd., Maverick Fund, L.D.C., Maverick Fund II, Ltd., Prentice Consumer Partners, LP and Rho Ventures VI, L.P.

 

The Company has entered into standard form
agreements with directors, officers and other employees related to grants under the Company’s stock incentive plans as well
as (in the case of officers and other employees) matters related to confidentiality, non-compete, non-solicitation and assignment
of inventions.

 

    	 

    	 

    
 

EXHIBIT A

 

FORM OF PRENTICE NOTES

 

[attached]

 

    	 

    	 

    
 

EXHIBIT B

 

FORM OF RHO NOTES

 

[attached]

 

    	 

    	 

    
 

EXHIBIT C

 

FORM OF PRENTICE & RHO WARRANT

 

[attached]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]